[an error occurred while processing this directive] ����Ƥ���Բ�ѧ��־ 2010, 36(5) 248-251 DOI:     ISSN: 2096-5540 CN: 32-1880/R

����Ŀ¼ | ����Ŀ¼ | ������� | �߼�����                                                            [��ӡ��ҳ]   [�ر�]
����
��չ����
������Ϣ
Supporting info
PDFȫ��
[HTMLȫ��]
�����
�����뷴��
�ѱ����Ƽ�������
�����ҵ����
�������ù�����
����
Email Alert
���·���
���������Ϣ
���Ĺؼ����������
Ƥ������
��ϸ��
�źŴ���
���������������
����ܰ
����
PubMed
Article by Li,H.X
Article by Lin,l

Ƥ��������ϸ���о���չ

����ܰ1,����2

1. �й�ҽѧ��ѧԺ���Ͼ�Ƥ�����о�����Ƥ�ڿơ�
2. �Ͼ� �й�ҽѧ��ѧԺ����Э��ҽѧԺƤ�����о���

ժҪ��

Ƥ��������ϸ����Ƥ����ϸ����һ���������ԣ�Ҳ�в����ԡ��Ѿ���ʶһЩƤ��������ϸ������ı�������CD34��CD44��ABC�����Ա��CD133�������ء�P63��CD20���ǵ���15��17�ͽǵ���19���Լ�������ص�Wnt/��-��������/c?۲mycͨ·��Hedgehog/Shh ���ź�ת��ͨ·��̽��Ƥ��������ϸ��������ϸ���������������ź�;���Ĺ�ϵ����Ϊ�����о�Ƥ��������ϸ�����ȵ����⡣����Ƥ��������ϸ�������Ǽ����ź�ͨ·���������ϸ��֮�����ͬ��������Ƥ��������ϸ�����²����ƣ�Ϊ�о�Ƥ�������ķ�����չ��ת�ƺ���Ч����Ƥ�������ṩ�µ�˼·��

�ؼ����� Ƥ������   ��ϸ��   �źŴ���  

Advances in skin tumor stem cell research

Abstract:

There is not only similarity but also difference between skin tumor stem cells and skin stem cells. Recently, some surface markers and related signal transduction pathway have been identified for skin tumor stem cells, such as CD34, CD44, members of ATP-binding cassette transporter ��ABC�� family, integrin, P63, CD20, keratin 15, 17 and 19, Wnt/��-catenin/c-myc pathway, Hedgehog/Shh pathways. The relationship between specific cell surface markers for skin tumor stem cells and signaling pathways has become the focus of researches into skin tumor stem cells. To clarify the similarity and difference in surface markers between skin tumor stem cells and skin stem cells will help to understand the pathogenic mechanism of skin tumor stem cells, and to offer new ideas for researches of initiation, progression, metastasis and effective treatment of skin tumors.

Keywords:
�ո����� 2010-04-15 �޻����� 2010-05-20 ����淢������ 2010-09-15 
DOI:
������Ŀ:

ͨѶ����: ����
���߼��:

�ο����ף�
[1] Fuchs E, Horsley V. More than one way to skin. Genes Dev, 2008. 22(8): 976-85. [2] Watt FM, Lo Celso C, Silva-Vargas V. Epidermal stem cells: an update. Curr Opin Genet Dev, 2006. 16(5): 518-24. [3] Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med, 1997. 3(7): 730-7. [4] Houghton J, Stoicov C, Nomura S, et al. Gastric cancer originating from bone marrow-derived cells. Science, 2004. 306(5701): 1568-71. [5] Aractingi S, Kanitakis J, Euvrard S, et al. Skin carcinoma arising from donor cells in a kidney transplant recipient. Cancer Res, 2005. 65(5): 1755-60. [6] Trempus CS, Morris RJ, Bortner CD, et al. Enrichment for living murine keratinocytes from the hair follicle bulge with the cell surface marker CD34. J Invest Dermatol, 2003. 120(4): 501-11. [7] Malanchi I, Peinado H, Kassen D, et al. Cutaneous cancer stem cell maintenance is dependent on beta-catenin signalling. Nature, 2008. 452(7187): 650-3. [8] Prince ME, Sivanandan R, Kaczorowski A, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A, 2007. 104(3): 973-8. [9] Choi CH. ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell Int, 2005. 5: 30. [10] Monzani E, Facchetti F, Galmozzi E, et al. Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer, 2007. 43(5): 935-46. [11] Frank NY, Margaryan A, Huang Y, et al. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res, 2005. 65(10): 4320-33. [12] Schatton T, Murphy GF, Frank NY, et al. Identification of cells initiating human melanomas. Nature, 2008. 451(7176): 345-9. [13] Klein WM, Wu BP, Zhao S, et al. Increased expression of stem cell markers in malignant melanoma. Mod Pathol, 2007. 20(1): 102-7. [14] Bongiorno MR, Doukaki S, Malleo F, et al. Identification of progenitor cancer stem cell in lentigo maligna melanoma. Dermatol Ther, 2008. 21 Suppl 1: S1-5. [15] Ambler CA, Maatta A. Epidermal stem cells: location, potential and contribution to cancer. J Pathol, 2009. 217(2): 206-16. [16] Gerdes MJ, Yuspa SH. The contribution of epidermal stem cells to skin cancer. Stem Cell Rev, 2005. 1(3): 225-31. [17] Pellegrini G, Dellambra E, Golisano O, et al. p63 identifies keratinocyte stem cells. Proc Natl Acad Sci U S A, 2001. 98(6): 3156-61. [18] Zabierowski SE, Herlyn M. Melanoma stem cells: the dark seed of melanoma. J Clin Oncol, 2008. 26(17): 2890-4. [19] Affara NI, Trempus CS, Schanbacher BL, et al. Activation of Akt and mTOR in CD34+/K15+ keratinocyte stem cells and skin tumors during multi-stage mouse skin carcinogenesis. Anticancer Res, 2006. 26(4B): 2805-20. [20] Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature, 2005. 434(7035): 843-50. [21] You L, He B, Xu Z, et al. An anti-Wnt-2 monoclonal antibody induces apoptosis in malignant melanoma cells and inhibits tumor growth. Cancer Res, 2004. 64(15): 5385-9. [22] Schatton T, Frank MH. Cancer stem cells and human malignant melanoma. Pigment Cell Melanoma Res, 2008. 21(1): 39-55. [23] Stecca B, Mas C, Clement V, et al. Melanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the RAS-MEK/AKT pathways. Proc Natl Acad Sci U S A, 2007. 104(14): 5895-900. [24] Hutchin ME, Kariapper MS, Grachtchouk M, et al. Sustained Hedgehog signaling is required for basal cell carcinoma proliferation and survival: conditional skin tumorigenesis recapitulates the hair growth cycle. Genes Dev, 2005. 19(2): 214-23. [25] Topczewska JM, Postovit LM, Margaryan NV, et al. Embryonic and tumorigenic pathways converge via Nodal signaling: role in melanoma aggressiveness. Nat Med, 2006. 12(8): 925-32. [26] Yilmaz OH, Valdez R, Theisen BK, et al. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature, 2006. 441(7092): 475-82.
�������������
1���,����Ⱥ.������ͷ�������������߼�Ƥ������[J]. ����Ƥ���Բ�ѧ��־, 2006,32(1): 20-
2������,����Ⱥ,κ־ƽ.��������Ƥ����������Ե��о���չ[J]. ����Ƥ���Բ�ѧ��־, 2006,32(2): 113-
3������,�����,Ϳ��ͥ.Stat3�����Ƥ����[J]. ����Ƥ���Բ�ѧ��־, 2006,32(3): 182-
4����԰԰,������.β-����������Ƥ������[J]. ����Ƥ���Բ�ѧ��־, 2008,34(4): 264-266
5���ܱ���,�浤,.����ͬԴ�Ѻ�������ι�Դ��Ƥ��������ʵ���о���չ[J]. ����Ƥ���Բ�ѧ��־, 2009,35(1): 27-29
6������ Ҷͥ· ����� ����� ������ ������ ��ά ���ѻ� Ҷͥ· ��ά.��ǻ�����෢Ƥ��ԭλ�����ͷֻ���״ϸ����һ��[J]. ����Ƥ���Բ�ѧ��־, 2009,35(3): 144-144
7����� ����.PI3K/Akt/mTOR�ź�ͨ·��Ƥ��������������[J]. ����Ƥ���Բ�ѧ��־, 2009,35(6): 382-384
8������ܰ ����.άA������Ƥ���������Ƶ��о���չ[J]. ����Ƥ���Բ�ѧ��־, 2010,36(6): 359-362
9������÷, ������.Ѫ�������Ļ��Ƽ���Ƥ����������м���е�����[J]. ����Ƥ���Բ�ѧ��־, 0,(): 361-363
10��ׯ��������, ����Ԫ��У.p53������Ƥ������[J]. ����Ƥ���Բ�ѧ��־, 1996,22(1): 22-25
11���ƽ����, �ィ����У.����������Ƥ�������ٴ��о��е�Ӧ��[J]. ����Ƥ���Բ�ѧ��־, 1996,22(2): 79-83
12������ΰ����, ����ɭ��У.Ƥ��������ϸ������[J]. ����Ƥ���Բ�ѧ��־, 1997,23(4): 206-208
13���º������, ��������У.Ƥ���еĻ��ʽ�������ø[J]. ����Ƥ���Բ�ѧ��־, 1999,25(2): 104-106
14����������, ���촺����, ��������У.�������յ�Ƥ�������γɻ���[J]. ����Ƥ���Բ�ѧ��־, 2001,27(5): 276-278
15�����M, Ϳ��ͥ.Ѫ����Ƥ�������Ӻ�Ƥ������[J]. ����Ƥ���Բ�ѧ��־, 2003,29(2): 97-99
16��������, ������.����Ƥ�������������Ƶ��о�[J]. ����Ƥ���Բ�ѧ��־, 2003,29(5): 270-272
17��������, ������.������ø-2��Ƥ�������е��о���չ[J]. ����Ƥ���Բ�ѧ��־, 2004,30(1): 48-50
18��������, ֣ï��, Ф����.HPV������ֲ����Ƥ�������о���չ[J]. ����Ƥ���Բ�ѧ��־, 2004,30(2): 120-122
19������, �浤.�в���������Ƥ�����������������Ƶ��о���չ[J]. ����Ƥ���Բ�ѧ��־, 2004,30(3): 170-172
20���■Ӣ, ����.p27��Ƥ������[J]. ����Ƥ���Բ�ѧ��־, 2004,30(4): 244-246
21�������, ������, ֣��.ϸ���źŴ���������Ƥ������[J]. ����Ƥ���Բ�ѧ��־, 2004,30(6): 393-395
22��������, �ィ��.����ø�������Ƽ���Ƥ�����������е�����[J]. ����Ƥ���Բ�ѧ��־, 2004,30(6): 396-398
23����ƽ, ��־��.UVB�շ�Ƥ�����ķ��ӻ����о���չ[J]. ����Ƥ���Բ�ѧ��־, 2005,31(1): 44-46
24����ӻ�, ���Ŀ�.Wnt�ź�ת��ͨ·������Ƥ�������е�����[J]. ����Ƥ���Բ�ѧ��־, 2005,31(2): 119-121
25������, ������, ��ѧ��.�෢�Լ�����ë����Ƥ���²�������о���չ[J]. ����Ƥ���Բ�ѧ��־, 2005,31(4): 250-252
26������÷, ������.Ѫ�������Ļ��Ƽ���Ƥ����������м���е�����[J]. ����Ƥ���Բ�ѧ��־, 0,(): 361-363
27���, ����Ⱥ, ��С��, ʯƽ��.������ͷ�������������߼�Ƥ������[J]. ����Ƥ���Բ�ѧ��־, 2006,32(1): 20-22
28������, ����Ⱥ, κ־ƽ.��������Ƥ����������Ե��о���չ[J]. ����Ƥ���Բ�ѧ��־, 2006,32(2): 113-116
29������, �����, Ϳ��ͥ.Stat3�����Ƥ����[J]. ����Ƥ���Բ�ѧ��־, 2006,32(3): 182-184
30����͢��, ��֮��.�鷿��Paget�������黯�о���չ[J]. ����Ƥ���Բ�ѧ��־, 2007,33(5): 308-310
31������÷, ������.Ѫ�������Ļ��Ƽ���Ƥ����������м���е�����[J]. ����Ƥ���Բ�ѧ��־, 2005,31(6): 361-363
32����ά �浤.Toll����������������Ƥ�������˼�Ƥ������[J]. ����Ƥ���Բ�ѧ��־, 2013,39(1): 59-62
33���򴺻�, �浤.���Ī������Ƥ���������о���չ[J]. ����Ƥ���Բ�ѧ��־, 2007,33(1): 22-24
34����ǿ, ������, �Ź���.�������Ƥ���޸��ϴ����Ƥ��ȱ��[J]. ����Ƥ���Բ�ѧ��־, 2007,33(3): 129-130
35���½�, �δ���, .���Ī�ؿ�Ƥ�����������û���[J]. ����Ƥ���Բ�ѧ��־, 2007,33(3): 136-138
36���Ժ��, ���.���ʽ�������ø������Ƥ������[J]. ����Ƥ���Բ�ѧ��־, 2007,33(3): 148-150
37���Ȳ� �ƽ��� ��ʢ��.�����߶�DNA�׻���Ӱ����о���չ[J]. ����Ƥ���Բ�ѧ��־, 2014,40(4): 267-269
38������ ��� ���� �浤.miRNA��Ƥ�������߹ⷴӦ�е�����[J]. ����Ƥ���Բ�ѧ��־, 2015,41(4): 243-245
39��ë��ϼ ��έѩ Фѧ�� �����.Notch�ź�ͨ·��Ƥ�������о���չ[J]. ����Ƥ���Բ�ѧ��־, 2016,42(2): 102-105

�������� (��ע��:��վʵ�������Ը�, �벻Ҫ������ѧ���޹ص�����!�������ݲ�����վ�۵�.)

Copyright 2008 by ����Ƥ���Բ�ѧ��־